<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83694</article-id><article-id pub-id-type="doi">10.7554/eLife.83694</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Study of efficacy and longevity of immune response to 3<sup>rd</sup> and 4<sup>th</sup> doses of COVID-19 vaccines in patients with cancer: a single arm clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-294436"><name><surname>Thakkar</surname><given-names>Astha</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7778-0752</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-271594"><name><surname>Pradhan</surname><given-names>Kith</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294439"><name><surname>Duva</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294438"><name><surname>Carreno</surname><given-names>Juan Manuel</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284828"><name><surname>Sahu</surname><given-names>Srabani</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294440"><name><surname>Thiruthuvanathan</surname><given-names>Victor</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294442"><name><surname>Campbell</surname><given-names>Sean</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294441"><name><surname>Gallego</surname><given-names>Sonia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294443"><name><surname>Bhagat</surname><given-names>Tushar D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294444"><name><surname>Rivera</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-271579"><name><surname>Choudhary</surname><given-names>Gaurav</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5365-6706</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294449"><name><surname>Olea</surname><given-names>Raul</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294450"><name><surname>Sabalza</surname><given-names>Maite</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-290290"><name><surname>Shapiro</surname><given-names>Lauren C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294451"><name><surname>Lee</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294452"><name><surname>Quinn</surname><given-names>Ryann</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294453"><name><surname>Mantzaris</surname><given-names>Ioannis</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294454"><name><surname>Chu</surname><given-names>Edward</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-271605"><name><surname>Will</surname><given-names>Britta</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294455"><name><surname>Pirofski</surname><given-names>Liise-anne</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-30733"><name><surname>Krammer</surname><given-names>Florian</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-271272"><name><surname>Verma</surname><given-names>Amit K</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5408-1673</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-294437"><name><surname>Halmos</surname><given-names>Balazs</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7548-8360</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Oncology</institution>, <institution>Albert Einstein College of Medicine</institution>, <addr-line><named-content content-type="city">Bronx</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Epidemiology and Population Health</institution>, <institution>Albert Einstein College of Medicine</institution>, <addr-line><named-content content-type="city">Bronx</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Microbiology</institution>, <institution>Icahn School of Medicine at Mount Sinai</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Pathology</institution>, <institution>Montefiore Medical Center</institution>, <addr-line><named-content content-type="city">Bronx</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution>Euroimmun</institution>, <addr-line><named-content content-type="city">Mountain Lakes</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Department of Medicine</institution>, <institution>Albert Einstein College of Medicine</institution>, <addr-line><named-content content-type="city">Bronx</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-190571"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing editor</role><aff><institution>DaVita Labs</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>amit.verma@einsteinmed.edu</email> (AV);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>bahalmos@Montefiore.org</email> (BH);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>03</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e83694</elocation-id><history><date date-type="received"><day>24</day><month>09</month><year>2022</year></date><date date-type="accepted"><day>05</day><month>03</month><year>2023</year></date></history><permissions><copyright-statement>Â© 2023, Thakkar et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Thakkar et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83694-v1.pdf"/><abstract><p><bold>Background:</bold> Cancer patients show increased morbidity with COVID-19 and need effective immunization strategies. Many healthcare regulatory agencies recommend administering 'booster' doses of COVID-19 vaccines beyond the standard 2-dose series, for this group of patients. Therefore, studying the efficacy of these additional vaccine doses against SARS-CoV-2 and variants of concern is of utmost importance in this immunocompromised patient population.</p><p><bold>Methods:</bold> We conducted a prospective single arm clinical trial enrolling patients with cancer that had received two doses of mRNA or one dose of AD26.CoV2.S vaccine and administered a 3rd dose of mRNA vaccine. We further enrolled patients that had no or low responses to three mRNA COVID vaccines and assessed the efficacy of a 4<sup>th</sup> dose of mRNA vaccine. Efficacy was assessed by changes in anti-spike antibody, T-cell activity and neutralization activity were again assessed at baseline and 4 weeks.</p><p><bold>Results:</bold> We demonstrate that a 3<sup>rd</sup> dose of COVID-19 vaccine leads to seroconversion in 57% of patients that were seronegative after primary vaccination series. The immune response is durable as assessed by anti-S antibody titers, T-cell activity and neutralization activity against wild-type SARS-CoV2 and BA1.1.529 at 6 months of follow up. A subset of severely immunocompromised hematologic malignancy patients that were unable to mount an adequate immune response (titer &lt;1000 AU/mL) after the 3<sup>rd</sup> dose and were treated with a 4<sup>th</sup> dose in a prospective clinical trial which led to adequate immune-boost in 67% of patients. Low baseline IgM levels and CD19 counts were associated with inadequate seroconversion. Booster doses induced limited neutralization activity against the Omicron variant.</p><p><bold>Conclusions:</bold> These results indicate that 3<sup>rd</sup> dose of COVID vaccine induces durable immunity in cancer patients and an additional dose can further stimulate immunity in a subset of patients with inadequate response.</p><p><bold>Funding:</bold> Leukemia lymphoma society, National Cancer Institute.</p><p><bold>Clinical trial identifier:</bold> NCT05016622.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>3P30CA013330-49S3</award-id><principal-award-recipient><name><surname>Halmos</surname><given-names>Balazs</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>NCI Community Oncology outreach program</institution></institution-wrap></funding-source><award-id>2UG1CA189859-06</award-id><principal-award-recipient><name><surname>Halmos</surname><given-names>Balazs</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>leukemia lymphoma society</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Verma</surname><given-names>Amit K</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Centers of Excellence for Influenza Research and Surveillance</institution></institution-wrap></funding-source><award-id>HHSN272201400008C</award-id><principal-award-recipient><name><surname>Krammer</surname><given-names>Florian</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>Centers of Excellence for Influenza Research and Response</institution></institution-wrap></funding-source><award-id>75N93021C00014</award-id><principal-award-recipient><name><surname>Krammer</surname><given-names>Florian</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Collaborative Influenza Vaccine Innovation Centers</institution></institution-wrap></funding-source><award-id>75N93019C00051</award-id><principal-award-recipient><name><surname>Krammer</surname><given-names>Florian</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>75N91019D00024</award-id><principal-award-recipient><name><surname>Krammer</surname><given-names>Florian</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Maite Sabalza, is affiliated with EUROIMMUN and has no financial interests to declare..</p></fn><fn fn-type="conflict" id="conf3"><p>Florian Krammer, The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2.(Serological Assay, U.S. Application Serial No. 17/913,783, NDV-HXP-S, U.S. Application Serial No. 17/922,777)..</p></fn><fn fn-type="conflict" id="conf4"><p>Amit K Verma, Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Ethics statement:The study was approved by Montefiore-Einstein institutional review board (IRB# 2021-13204). Participants were recruited after referral to the study from their treating oncologists. At the consent visit, patients were provided with a study overview including initial lab draw, vaccine appointment and follow-up at pre-specified time points. The informed consent document included consent for research samples and consent to protect confidential patient information by the personnel approved under the IRB. Any person not involved with the research study did not have access to patient identifying data. De-identified data was allowed to be shared with collaborators and findings from the study be published. The informed consent document also included consent for a future research lab draw should an improved test for SARS-CoV-2 immunity became available. Finally, the consent included patient's right to withdraw from the study at any time. The patient was provided with a copy of the signed informed consent.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The data for this clinical trial contains protected health information for the participants that includes a large amount of information as to specific dates/treatments/cancer diagnoses. Therefore, it is prudent to protect this information and it does not seem appropriate to put the information out in the public domain. For example- patients' specific cancer diagnoses, treatment received, COVID-19 vaccine dates can be viewed as sensitive information in the aggregate. If we remove this detailed information from the dataset then the dataset would end up being very limited and not useful for any researcher. Therefore, we believe that making the dataset available through the corresponding author based on individual well-supported requests will allow researchers access to complete data while protecting potentially identifiable patient-level information from the public domain. We are more than happy to share the deidentified database with the reviewers/editors (for review purposes only). If an interested researcher wishes to acquire the data, the aforementioned de-identified dataset can be made available by contacting the corresponding author of the study. While there are no restrictions on data usage per se, we request that future research be done in accordance with standardized guidelines and with local ethics approval. The code is already deposited in GitHubCode availability statement : Computer code has been deposited in GitHub and can be found at https://github.com/kith-pradhan/CovidBooster and https://github.com/kith-pradhan/CovidBooster4th</p></sec><supplementary-material><ext-link xlink:href="elife-83694-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>